Treatment of breast cancer by bone marrow transplantation (BMT) after chemotherapy has been limited after initial negative studies.
But UAB cancer specialist William A. Vaughan, M.D., says a longer view may re-establish this treatment's reputation. "Overreaction to early results created an irrational exuberance against the treatment. Those early studies had limited power and too short of a follow-up to be conclusive.
He says unpublished reports from The Netherlands "suggest that a modest statistically significant benefit in disease-free and overall survival may ultimately be demonstrated."
He presented these data at a meeting of the National Comprehensive Cancer Network last month. UAB's Comprehensive Cancer Center performs 5-10 highly selected cases yearly.
Contact Hank Black, Media Relations, 205-934-8938 or [email protected].
RSS